1. Jinek, M. et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337, 816–821 (2012).

2. Cong, L. et al. Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819–823 (2013).

3. Mali, P. et al. RNA-guided human genome engineering via Cas9. Science 339, 823–826 (2013).

4. Cho, S. W., Kim, S., Kim, J. M. & Kim, J. S. Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat. Biotechnol. 31, 230–232 (2013).

5. Zetsche, B. et al. Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR–Cas system. Cell 163, 759–771 (2015).

6. Swiech, L. et al. In vivo interrogation of gene function in the mammalian brain using CRISPR–Cas9. Nat. Biotechnol. 33, 102–106 (2015).

7. Mingozzi, F. & High, K. A. Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood 122, 23–36 (2013).

8. Ishida, K., Gee, P. & Hotta, A. Minimizing off-target mutagenesis risks caused by programmable nucleases. Int. J. Mol. Sci. 16, 24751–24771 (2015).

9. Watakabe, A. et al. Comparative analyses of adeno-associated viral vector serotypes 1, 2, 5, 8 and 9 in marmoset, mouse and macaque cerebral cortex. Neurosci. Res. 93, 144–157 (2015).

10. Staahl, B. T. et al. Efficient genome editing in the mouse brain by local delivery of engineered Cas9 ribonucleoprotein complexes. Nat. Biotechnol. 35, 431–434 (2017).

11. Kazdoba, T. M., Leach, P. T., Silverman, J. L. & Crawley, J. N. Modeling fragile X syndrome in the Fmr1 knockout mouse. Intractable Rare Dis. Res. 3, 118–133 (2014).

12. Persico, A. M. & Napolioni, V. Autism genetics. Behav. Brain Res. 251, 95–112 (2013).

13. Ji, N. Y. & Findling, R. L. Pharmacotherapy for mental health problems in people with intellectual disability. Curr. Opin. Psychiatry 29, 103–125 (2016).

14. Politte, L. C., Henry, C. A. & McDougle, C. J. Psychopharmacological interventions in autism spectrum disorder. Harv. Rev. Psychiatry 22, 76–92 (2014).

15. Bear, M. F., Huber, K. M. & Warren, S. T. The mGluR theory of fragile X mental retardation. Trends Neurosci. 27, 370–377 (2004).

16. Bear, M. F. Therapeutic implications of the mGluR theory of fragile X mental retardation. Genes Brain Behav. 4, 393–398 (2005).

17. Dölen, G. & Bear, M. F. Role for metabotropic glutamate receptor 5 (mGluR5) in the pathogenesis of fragile X syndrome. J. Physiol. 586, 1503–1508 (2008).

18. Osterweil, E. K., Krueger, D. D., Reinhold, K. & Bear, M. F. Hypersensitivity to mGluR5 and ERK1/2 leads to excessive protein synthesis in the hippocampus of a mouse model of fragile X syndrome. J. Neurosci. 30, 15616–15627 (2010).

19. Tao, J. et al. Negative allosteric modulation of mGluR5 partially corrects pathophysiology in a mouse model of Rett syndrome. J. Neurosci. 36, 11946–11958 (2016).

20. Silverman, J. L. et al. Negative allosteric modulation of the mGluR5 receptor reduces repetitive behaviors and rescues social deficits in mouse models of autism. Sci. Transl. Med. 4, 131ra151 (2012).

21. Jacquemont, S. et al. Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. Sci. Transl. Med. 3, 64ra61 (2011).

22. Raspa, M., Wheeler, A. C. & Riley, C. Public health literature review of fragile X syndrome. Pediatrics 139, S153–S171 (2017).

23. Lee, K. et al. Nanoparticle delivery of Cas9 ribonucleoprotein and donor DNA in vivo induces homology-directed DNA repair. Nat. Biomed. Eng. 1, 889–901 (2017).

24. Feng, G. et al. Imaging neuronal subsets in transgenic mice expressing multiple spectral variants of GFP. Neuron 28, 41–51 (2000).

25. Choi, G. B. et al. Driving opposing behaviors with ensembles of piriform neurons. Cell 146, 1004–1015 (2011).

26. Fried, I., Mukamel, R. & Kreiman, G. Internally generated preactivation of single neurons in human medial frontal cortex predicts volition. Neuron 69, 548–562 (2011).

27. McMahon, M. A. & Cleveland, D. W. Gene therapy: gene-editing therapy for neurological disease. Nat. Rev. Neurol. 13, 7–9 (2017).

28. Xie, N. et al. Reactivation of FMR1 by CRISPR/Cas9-mediated deletion of the expanded CGG-repeat of the fragile X chromosome. PLoS ONE 11, e0165499 (2016).

29. Park, C. Y. et al. Reversion of FMR1 methylation and silencing by editing the triplet Repeats in fragile X iPSC-derived neurons. Cell Rep. 13, 234–241 (2015).

30. Madisen, L. et al. A robust and high-throughput Cre reporting and characterization system for the whole mouse brain. Nat. Neurosci. 13, 133–140 (2010).

31. Chen, Y. S. et al. Size-dependent impairment of cognition in mice caused by the injection of gold nanoparticles. Nanotechnology 21, 485102 (2010).

32. Ferreira, G. K. et al. Effect of acute and long-term administration of gold nanoparticles on biochemical parameters in rat brain. Mater. Sci. Eng. C Mater. Biol. Appl. 79, 748–755 (2017).

33. Almad, A. A. & Maragakis, N. J. Glia: an emerging target for neurological disease therapy. Stem Cell Res. Ther. 3, 37 (2012).

34. Sukoff Rizzo, S. J. & Crawley, J. N. Behavioral phenotyping assays for genetic mouse models of neurodevelopmental, neurodegenerative, and psychiatric disorders. Annu. Rev. Anim. Biosci. 5, 371–389 (2017).

35. Kim, H., Lim, C. S. & Kaang, B. K. Neuronal mechanisms and circuits underlying repetitive behaviors in mouse models of autism spectrum disorder. Behav. Brain Funct. 12, 3 (2016).

36. Spencer, C. M. et al. Modifying behavioral phenotypes in Fmr1 KO mice: genetic background differences reveal autistic-like responses. Autism Res. 4, 40–56 (2011).

37. Sungur, A., Vörckel, K. J., Schwarting, R. K. & Wöhr, M. Repetitive behaviors in the Shank1 knockout mouse model for autism spectrum disorder: developmental aspects and effects of social context. J. Neurosci. Methods 234, 92–100 (2014).

38. Ding, Q., Sethna, F. & Wang, H. Behavioral analysis of male and female Fmr1 knockout mice on C57BL/6 background. Behav. Brain Res. 271, 72–78 (2014).

39. Graham, D. R. & Sidhu, A. Mice expressing the A53T mutant form of human alpha-synuclein exhibit hyperactivity and reduced anxiety-like behavior. J. Neurosci. Res. 88, 1777–1783 (2010).

40. Masuda, T., Tsuda, M., Tozaki-Saitoh, H. & Inoue, K. Lentiviral transduction of cultured microglia. Methods Mol. Biol. 1041, 63–67 (2013).

41. Balcaitis, S., Weinstein, J. R., Li, S., Chamberlain, J. S. & Möller, T. Lentiviral transduction of microglial cells. Glia. 50, 48–55 (2005).

42. Burke, B., Sumner, S., Maitland, N. & Lewis, C. E. Macrophages in gene therapy: cellular delivery vehicles and in vivo targets. J. Leukoc. Biol. 72, 417–428 (2002).

43. Kim, H. J. et al. Introduction of stearoyl moieties into a biocompatible cationic polyaspartamide derivative, PAsp(DET), with endosomal escaping function for enhanced siRNA-mediated gene knockdown. J. Control. Release 145, 141–148 (2010).

44. Miyata, K. et al. Polyplexes from poly(aspartamide) bearing 1,2-diaminoethane side chains induce pH-selective, endosomal membrane destabilization with amplified transfection and negligible cytotoxicity. J. Am. Chem. Soc. 130, 16287–16294 (2008).

45. Tabebordbar, M. et al. In vivo gene editing in dystrophic mouse muscle and muscle stem cells. Science 351, 407–411 (2016).

46. Zhang, X., Servos, M. R. & Liu, J. Instantaneous and quantitative functionalization of gold nanoparticles with thiolated DNA using a pH-assisted and surfactant-free route. J. Am. Chem. Soc. 134, 7266–7269 (2012).

47. Lee, H. Y. et al. Bidirectional regulation of dendritic voltage-gated potassium channels by the fragile X mental retardation protein. Neuron 72, 630–642 (2011).

48. Khan, M. & Gasser, S. Generating primary fibroblast cultures from mouse ear and tail tissues. J. Vis. Exp. 107, 53565 (2016).

49. Lin, S., Staahl, B. T., Alla, R. K. & Doudna, J. A. Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery. elife 3, e04766 (2014).

50. Sanjana, N. E., Shalem, O. & Zhang, F. Improved vectors and genome-wide libraries for CRISPR screening. Nat. Methods 11, 783–784 (2014).

51. Güuell, M., Yang, L. & Church, G. M. Genome editing assessment using CRISPR Genome Analyzer (CRISPR-GA). Bioinformatics 30, 2968–2970 (2014).

52. Brinkman, E. K., Chen, T., Amendola, M. & van Steensel, B. Easy quantitative assessment of genome editing by sequence trace decomposition. Nucleic Acids Res. 42, e168 (2014).

53. McFarlane, H. G. et al. Autism-like behavioral phenotypes in BTBR T+tf/J mice. Genes Brain Behav. 7, 152–163 (2008).